66 related articles for article (PubMed ID: 19690194)
1. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Bosman FT; Yan P; Tejpar S; Fiocca R; Van Cutsem E; Kennedy RD; Dietrich D; Roth A
Clin Cancer Res; 2009 Sep; 15(17):5528-33. PubMed ID: 19690194
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
3. Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?
Sinicrope FA; Shi Q
J Natl Cancer Inst; 2012 Nov; 104(21):1616-8. PubMed ID: 23104213
[No Abstract] [Full Text] [Related]
4. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
5. Integrative approach for prioritizing cancer genes in sporadic colon cancer.
Reid JF; Gariboldi M; Sokolova V; Capobianco P; Lampis A; Perrone F; Signoroni S; Costa A; Leo E; Pilotti S; Pierotti MA
Genes Chromosomes Cancer; 2009 Nov; 48(11):953-62. PubMed ID: 19672874
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Ogino S; Meyerhardt JA; Cantor M; Brahmandam M; Clark JW; Namgyal C; Kawasaki T; Kinsella K; Michelini AL; Enzinger PC; Kulke MH; Ryan DP; Loda M; Fuchs CS
Clin Cancer Res; 2005 Sep; 11(18):6650-6. PubMed ID: 16166444
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
[TBL] [Abstract][Full Text] [Related]
10. A novel K-ras mutation in colorectal cancer. A case report and literature review.
Palmirotta R; Savonarola A; Formica V; Ludovici G; Del Monte G; Roselli M; Guadagni F
Anticancer Res; 2009 Aug; 29(8):3369-74. PubMed ID: 19661358
[TBL] [Abstract][Full Text] [Related]
11. TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
Kandioler D; Mittlböck M; Kappel S; Puhalla H; Herbst F; Langner C; Wolf B; Tschmelitsch J; Schippinger W; Steger G; Hofbauer F; Samonigg H; Gnant M; Teleky B; Kührer I;
EBioMedicine; 2015 Aug; 2(8):825-30. PubMed ID: 26425688
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
Barault L; Veyrie N; Jooste V; Lecorre D; Chapusot C; Ferraz JM; Lièvre A; Cortet M; Bouvier AM; Rat P; Roignot P; Faivre J; Laurent-Puig P; Piard F
Int J Cancer; 2008 May; 122(10):2255-9. PubMed ID: 18224685
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
Grothey A; Sargent DJ
JAMA Oncol; 2016 Sep; 2(9):1133-4. PubMed ID: 27273467
[No Abstract] [Full Text] [Related]
14. Recent approaches to identifying biomarkers for high-risk stage II colon cancer.
Akiyoshi T; Kobunai T; Watanabe T
Surg Today; 2012 Nov; 42(11):1037-45. PubMed ID: 22961195
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine and squamous colonic composite carcinoma: case report with molecular analysis.
Wentz SC; Vnencak-Jones C; Chopp WV
World J Gastroenterol; 2011 Nov; 17(42):4729-33. PubMed ID: 22180717
[TBL] [Abstract][Full Text] [Related]
16. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Nygård SB; Vainer B; Nielsen SL; Bosman F; Tejpar S; Roth A; Delorenzi M; Brünner N; Budinska E
Clin Cancer Res; 2016 Apr; 22(7):1621-31. PubMed ID: 26542057
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
Tejpar S; Bertagnolli M; Bosman F; Lenz HJ; Garraway L; Waldman F; Warren R; Bild A; Collins-Brennan D; Hahn H; Harkin DP; Kennedy R; Ilyas M; Morreau H; Proutski V; Swanton C; Tomlinson I; Delorenzi M; Fiocca R; Van Cutsem E; Roth A
Oncologist; 2010; 15(4):390-404. PubMed ID: 20350999
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.
Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K
Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861
[TBL] [Abstract][Full Text] [Related]
19. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
